EA200300266A1 - Новые сложные эфиры апорфина и их применение в терапии - Google Patents

Новые сложные эфиры апорфина и их применение в терапии

Info

Publication number
EA200300266A1
EA200300266A1 EA200300266A EA200300266A EA200300266A1 EA 200300266 A1 EA200300266 A1 EA 200300266A1 EA 200300266 A EA200300266 A EA 200300266A EA 200300266 A EA200300266 A EA 200300266A EA 200300266 A1 EA200300266 A1 EA 200300266A1
Authority
EA
Eurasian Patent Office
Prior art keywords
application
aporfin
therapy
derivatives
new complex
Prior art date
Application number
EA200300266A
Other languages
English (en)
Other versions
EA006388B1 (ru
Inventor
Хокан Викстрем
Дюрк Дейкстра
Томас Кремерс
Пер Эрик Андрен
Сандрин Марше
Ульрик Юрва
Original Assignee
Аксон Биокемикалс Б.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Аксон Биокемикалс Б.В. filed Critical Аксон Биокемикалс Б.В.
Publication of EA200300266A1 publication Critical patent/EA200300266A1/ru
Publication of EA006388B1 publication Critical patent/EA006388B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/18—Ring systems of four or more rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

Описаны новые производные апорфина, которые имеют формулу (I), или их физиологически приемлемые соли. Указанные производные могут быть применены с целью лечения болезни Паркинсона, мигрени, синдрома усталых ног (RLS), полового нарушения у мужчин и женщин, гиперпролактинемии и психотических расстройств и/или оценки болезни Паркинсона. Также описаны способы получения таких производных.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200300266A 2000-08-17 2001-07-20 Сложные эфиры апорфина и их применение в терапии EA006388B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0002934A SE0002934D0 (sv) 2000-08-17 2000-08-17 New aporphine esters and in their use in therapy
PCT/SE2001/001658 WO2002014279A1 (en) 2000-08-17 2001-07-20 New aporphine esters and their use in therapy

Publications (2)

Publication Number Publication Date
EA200300266A1 true EA200300266A1 (ru) 2003-08-28
EA006388B1 EA006388B1 (ru) 2005-12-29

Family

ID=20280719

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200300266A EA006388B1 (ru) 2000-08-17 2001-07-20 Сложные эфиры апорфина и их применение в терапии

Country Status (19)

Country Link
US (3) US7238705B2 (ru)
EP (1) EP1309553A1 (ru)
JP (1) JP2004506041A (ru)
KR (1) KR100865503B1 (ru)
CN (1) CN1242991C (ru)
AU (2) AU2001271228B2 (ru)
BR (1) BR0113291A (ru)
CA (1) CA2419842C (ru)
CZ (1) CZ2003454A3 (ru)
EA (1) EA006388B1 (ru)
HU (1) HUP0301685A3 (ru)
IL (2) IL154096A0 (ru)
MX (1) MXPA03001465A (ru)
NO (1) NO324409B1 (ru)
NZ (1) NZ523893A (ru)
PL (1) PL360089A1 (ru)
SE (1) SE0002934D0 (ru)
WO (1) WO2002014279A1 (ru)
ZA (1) ZA200300828B (ru)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102036D0 (sv) * 2001-06-08 2001-06-08 Axon Biochemicals Bv Pharmaceutical formulation for the efficient administration of apomorphine, 6aR- (-) -N- Propyl- norapomorphine and their derivatives and pro-drugs thereof
SE0002934D0 (sv) 2000-08-17 2000-08-17 Axon Biochemicals Bv New aporphine esters and in their use in therapy
JP2006527699A (ja) * 2003-06-19 2006-12-07 美時化学製薬股▲ふん▼有限公司 アポルフィン、及び、ケトンアポルフィン化合物とその用途
EP1644004A4 (en) 2003-06-20 2010-10-06 Ronald Aung-Din LOCAL THERAPY FOR THE TREATMENT OF MIGRAINS, MUSCLE CLARIFICATIONS, MUSCLE SPASMS, SPASTICITY AND RELATED CONDITIONS
CA2562465A1 (en) 2004-04-13 2005-10-27 The Mclean Hospital Corporation R(-)-11-hydroxyaporphine derivatives and uses thereof
GB2437488A (en) * 2006-04-25 2007-10-31 Optinose As Pharmaceutical oily formulation for nasal or buccal administration
US20110111014A1 (en) * 2007-06-26 2011-05-12 Parkinson's Institute Methods and compositions for treatment of neurological disorders
WO2009009083A1 (en) * 2007-07-12 2009-01-15 The Mclean Hospital Corporation R(-)-2-methoxy-11-hydroxyaporphine and derivatives thereof
US8129530B2 (en) 2007-08-31 2012-03-06 H. Lundbeck A/S Catecholamine derivatives and prodrugs thereof
TWI404702B (zh) * 2007-08-31 2013-08-11 Lundbeck & Co As H 兒茶酚胺衍生物和其前藥
ES2315203B1 (es) * 2007-09-11 2010-01-13 Universidade De Santiago De Compostela Uso de oxoisoaporfinas y sus derivados como inhibidores selectivos de la monoamino oxidasa a.
GB0721394D0 (en) * 2007-10-31 2007-12-12 Vectura Group Plc Compositions for trating parkinson's disease
JP2011526889A (ja) 2008-06-30 2011-10-20 アフギン ファーマ，エルエルシー 局所局部的神経作用療法
WO2010121159A1 (en) * 2009-04-17 2010-10-21 Somalabs, Inc. Method for the induction of a reward response by modulation of dopaminergic systems in the central nervous system
JP5760295B2 (ja) 2009-06-12 2015-08-05 シナプサス セラピューティクス，インコーポレーテッド 舌下用アポモルフィン
EA031156B1 (ru) 2010-12-16 2018-11-30 Суновион Фармасьютикалз Инк. Сублингвальные пленки
EP2683393B1 (en) * 2011-02-11 2018-04-11 The Regents of The University of Michigan Tripeptide compositions and their use for treatment of diabetes
CA3019769C (en) 2015-04-21 2021-10-12 Sunovion Pharmaceuticals Inc. Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa
WO2016207070A1 (en) 2015-06-24 2016-12-29 Koninklijke Philips N.V. Sweat monitoring apparatus and monitoring method
CA3088824A1 (en) * 2018-01-18 2019-07-25 Leukos Biotech, S. L. Apomorphine·palmitic acid cocrystal solid particle crystalline form
CA3097568A1 (en) * 2018-04-20 2019-10-24 The General Hospital Corporation Acetylated prodrugs for delivery across the blood-brain barrier

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4080456A (en) * 1971-10-26 1978-03-21 Schering Aktiengesellschaft Diacylapomorphines
AU3140577A (en) * 1976-12-13 1979-06-14 Sterling Drug Inc N-propylnorapormorphine diesters
DE2717001C2 (de) * 1977-04-18 1984-06-20 Karl O. Helm Ag, 2000 Hamburg Arzneimittel mit antithrombotischer Wirkung
DE3171561D1 (en) * 1980-05-08 1985-09-05 Univ Northeastern N-substituted aporphines, a method of inducing emesis and a method of controlling psychosis utilising the same
US4353912A (en) * 1980-05-08 1982-10-12 Northeastern University N-Haloalkyl nor apomorphines and method of inactivating dopamine receptor sites and enhancing dopaminergic activity therewith
WO1990012574A1 (en) * 1989-04-25 1990-11-01 Northeastern University Dopamine agonist compounds
GB9517062D0 (en) 1995-08-18 1995-10-25 Scherer Ltd R P Pharmaceutical compositions
GB9700878D0 (en) 1997-01-17 1997-03-05 Scherer Ltd R P Dosage forms and method for ameliorating male erectile dysfunction
US6403605B1 (en) 1998-05-29 2002-06-11 Queen's University At Kingston Methods for the normalization of sexual response and amelioration of long term genital tissue degradation
IT1299566B1 (it) * 1998-07-17 2000-03-16 Ifi Istituto Farmacoterapico I Cerotto transdermico e composizioni farmaceutiche comprendenti r (-)- norapropilapomorfina cloridrato e/o s (+) - norapropilapomorfina
CA2371551A1 (en) * 1999-05-13 2000-11-23 Mario Baraldi Pharmaceutical compositions comprising apocodeine and/or its derivatives
CN1471395A (zh) * 2000-04-07 2004-01-28 ����ҽҩƷ���޹�˾ 阿扑吗啡衍生物及其使用方法
SE0002934D0 (sv) 2000-08-17 2000-08-17 Axon Biochemicals Bv New aporphine esters and in their use in therapy
SE0102036D0 (sv) * 2001-06-08 2001-06-08 Axon Biochemicals Bv Pharmaceutical formulation for the efficient administration of apomorphine, 6aR- (-) -N- Propyl- norapomorphine and their derivatives and pro-drugs thereof
EP1950203A1 (en) 2007-01-24 2008-07-30 Laboratorios del Dr. Esteve S.A. Substituted pyrazoline compounds with ACAT, their preparation and use as medicaments

Also Published As

Publication number Publication date
US20080119504A1 (en) 2008-05-22
HUP0301685A2 (hu) 2003-08-28
KR20030036703A (ko) 2003-05-09
KR100865503B1 (ko) 2008-10-28
US20040018956A1 (en) 2004-01-29
BR0113291A (pt) 2004-01-06
HUP0301685A3 (en) 2010-03-29
NZ523893A (en) 2003-10-31
IL154096A (en) 2009-11-18
ZA200300828B (en) 2004-05-17
US20050143408A1 (en) 2005-06-30
US7238705B2 (en) 2007-07-03
US7332503B2 (en) 2008-02-19
SE0002934D0 (sv) 2000-08-17
AU2001271228B2 (en) 2006-02-02
EA006388B1 (ru) 2005-12-29
WO2002014279A1 (en) 2002-02-21
CA2419842A1 (en) 2002-02-21
AU7122801A (en) 2002-02-25
CA2419842C (en) 2011-10-18
EP1309553A1 (en) 2003-05-14
MXPA03001465A (es) 2004-12-13
NO324409B1 (no) 2007-10-08
NO20030677L (no) 2003-03-05
PL360089A1 (en) 2004-09-06
CN1447792A (zh) 2003-10-08
NO20030677D0 (no) 2003-02-11
CZ2003454A3 (cs) 2003-06-18
IL154096A0 (en) 2003-07-31
JP2004506041A (ja) 2004-02-26
CN1242991C (zh) 2006-02-22

Similar Documents

Publication Publication Date Title
EA200300266A1 (ru) Новые сложные эфиры апорфина и их применение в терапии
EA200300171A1 (ru) Циклопентаноиндолы, композиции, содержащие данные соединения, и способы лечения
EA200201214A1 (ru) Замещенные тиоацетамиды
EA200300293A1 (ru) Противовоспалительные конденсированные пирролокарбазолы
EA200001223A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
EA200100971A1 (ru) Новые соединения и композиции в качестве ингибиторов протеазы
EA200300527A1 (ru) Новые способы лечения синдрома "усталых ног"
EA200300929A1 (ru) Новые лекарственные композиции на основе антихолинергических средств и ингибиторов pde-iv
EP1248612A4 (en) NEW SUBSTANCES AND COMPOUNDS AS PROTEASE INHIBITORS
NO20093464L (no) Nye medikamentblandinger basert pa anti-cholinergisk effektive forbindelser og beta-mimetika
EA200200249A1 (ru) Производные 3(5)-уреидопиразола, способ их получения и их применение в качестве противоопухолевых агентов
JO2503B1 (en) Benzathiazole derivatives
ATE466580T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE468336T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE365733T1 (de) Zusammensetzungen brauchbar als protein-kinase- inhibitoren
CU23208A3 (es) Oxazolidinonas sustituidas y su uso en el campo de la coagulacion sanguinea
EA199800563A1 (ru) Антагонисты гормона, высвобождающего гонадотропин
EA200200208A1 (ru) Синергитическая композиция
EA200201179A1 (ru) Производные 2-аминокарбонил-9h-пурина
BRPI0410649A (pt) benzo(b) tiofeno 3-arilóxi e 3-heteroarilóxi substituìdos como agentes terapêuticos com atividade pi3k
EA200300503A1 (ru) Новые лекарственные композиции на основе солей тиотропия и солей салметерола
IS8521A (is) Þríhringlaga indólhýdróxýetýlamínafleiður og notkun þeirra í meðhöndlun á Alzheimerssjúkdómi
EA200100284A1 (ru) Агонисты 5ht1 рецепторов и метоклопрамид для лечения мигрени
EA200400357A1 (ru) Дезинтегрирующиеся в ротовой полости композиции валдекоксиба
CY1109808T1 (el) Αρυλινδενο-πυριδινες και αρυλινδενο-πυριμιδινες και η χρηση τους ως ανταγωνιστων των υποδοχεων αδενοσινης α2α

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU